Recently, iiMedia Research, a globally leading third-party data mining and analysis institution for the new economy industry, released the "Top 40 Leading Chinese Innovative Drug Companies Going Global in 2025" at the 2025 Business and Philanthropy Forum held in Singapore. Biokin Pharmaceutical ranked seventh on the list.

This ranking is China's first authoritative list focused on innovative drugs going global. Its evaluation relies on iiMedia's independently developed “China Mobile Internet Big Data Mining and Analysis System (CMDAS)” and employs the iiMeval big data evaluation model for calculation and assignment. It analyzes and calculates scores based on dimensions including R&D strength, revenue scale, market performance, overseas expansion, and product portfolio, combined with analyst ratings. The evaluation places particular emphasis on factors such as overseas revenue, product pipeline, and R&D capabilities. Scores range from 0 to 100 points, with higher scores indicating stronger comprehensive capabilities of the company and its products within their respective fields.

As one of China's representative enterprise in global innovative drug marketing, Biokin Pharmaceutical has consistently pursued a dual-track strategy of “independent R&D + international collaboration” to accelerate the internationalization of its innovative drugs. On November 17, 2025, Iza-bren (an EGFR×HER3 bispecific ADC), independently developed by Biokin Pharmaceutical, achieved dual endpoints of PFS and OS in a late-stage esophageal cancer study. This milestone signifies that China's innovative pharmaceutical companies are driving global healthcare transformation with core technologies, marking another significant advancement in this field.